Kenbe, Yes managed care and other third party paye

Kenbe, Yes managed care and other third party payers will be initiating price controls over time, but what every investor needs to remember is the market will still grow and SCRC has positioned itself as a BIG PLAYER. Mr. Schneiderman has position SCRC to maximize this opportunity. I share your enthusiasm about RapiMeds. Although one poster stated RapiMeds was on "indefinite hold", I never believed that it was. Mr. Schneiderman continues to believe RapiMeds will mirror compounding's success and I believe him. I have heard from others who have practically given up on RapiMeds now seeing the future potential it will add to the bottom line and financial strength of the company. PIMD will also be adding significantly to the bottom line. It has been a long time coming and I know, me included, have stated "our time has come" for months. Well, I'll say it again, our time has finally arrived. These next few months are going to tell the future of SCRC and I believe it will be nothing less than HISTORIC! Yes, SCRC is on the verge of greatness. Q3 & Q4 results, just like Celtics predicted months ago, will set the stage for incredible growth and opportunity for this little $58.8 annual run rate company. $58.8M, not bad at all.